A prospective feasibility study of cord blood transplant using once daily intravenous busulfan and fludarabine plus melphalan as conditioning regime
Not Applicable
- Conditions
- Hematological malignancy
- Registration Number
- JPRN-UMIN000030308
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Because the schedule of treatment in this study was approved by the government, we decided to stop this trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
(1) patients with organ dysfunction (lung, renal, liver, heart) (2) patients who are expected not to survive 100 days or longer (3) patients with another active cancer (4) pregnant or breast-feeding (5) patients with mental disorder (6) the physician consider inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Engraftment rate
- Secondary Outcome Measures
Name Time Method (1) non-relapse mortality rate at 100 days after CBT (2) SOS rate at 100 days after CBT (3) 1-year overall survival and relapse rates